In a recent randomized phase 2 trial, investigators examined the combination of gemcitabine and cisplatin with or without the PARP inhibitor in the frontline treatment of patients with pancreatic ductal adenocarcinomas and a germline BRCA1/2 or PALB2 mutation, says Mizrahi.Investigators wanted to evaluate whether the addition of a PARP inhibitor to chemotherapy would improve the effectiveness of chemotherapy in this patient population. Watch here . . .
Jonathan Mizrahi, MD, fellow at The University of Texas MD Anderson Cancer Center, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.